U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06859788) titled 'SPI-1005 for the Treatment of Meniere's Disease (Open Label)' on Feb. 28.
Brief Summary: Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Meniere's Disease
Meniere's Disease
Intervention:
DRUG: Ebselen
Glutathione peroxidase mimetic
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sound Pharmaceuticals, Incorporated
Published by HT Digital Content Services with permission from Health Daily Digest....